Article
Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
European radiology - 1 Jan 2024
Klimeš Filip, Voskrebenzev Andreas, Gutberlet Marcel, Speth Milan, Grimm Robert, Dohna Martha, Hansen Gesine, Wacker Frank, Renz Diane Miriam, Dittrich Anna-Maria, Vogel-Claussen Jens
Abstract excerpt
OBJECTIVES: To investigate whether 3D phase-resolved functional lung (PREFUL)-MRI parameters are suitable to measure response to elexacaftor/tezacaftor/ivacaftor (ETI) therapy and their association with clinical outcomes in cystic fibrosis (CF) patients. METHODS: Twenty-three patients with CF (mean age: 21; age range: 14-46) underwent MRI examination at baseline and 8-16 weeks after initiation of ETI....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
